Black Diamond Therapeutics (BDTX) vs Cardiff Oncology (CRDF)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cardiff Oncology (CRDF) has outperformed Black Diamond Therapeutics (BDTX) over the past year, losing 54.6% versus a loss of 54.6%. Over five years, BDTX leads with a -77.9% price change compared with -83.1% for CRDF. Black Diamond Therapeutics is the larger company by market cap ($104.9 million vs $84.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BDTX | CRDF |
|---|---|---|
| Share price | $1.83 | $1.08 |
| Market cap | $104.86M | $84.02M |
| 1-day change | +1.10% | +1.89% |
| YTD return | -25.51% | -61.57% |
| 1-year return | -54.64% | -54.62% |
| 5-year return | -77.87% | -83.13% |
| EPS (TTM) | $-0.75 | $-0.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.94 | $3.31 |
| 52-week low | $1.60 | $0.76 |
| Distance from 52-week high | -62.96% | -67.37% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +446.45% | +437.96% |
| Average volume | 624.32K | 1.05M |
| Shares outstanding | 57.30M | 77.80M |
| Employees | 21 | 30 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Black Diamond Therapeutics
BDTX stock →Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 21 employees
About Cardiff Oncology
CRDF stock →Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 30 employees
BDTX vs CRDF FAQ
Which is bigger, Black Diamond Therapeutics or Cardiff Oncology?
Black Diamond Therapeutics (BDTX) is larger, with a market capitalization of $104.86M compared with $84.02M for Cardiff Oncology (CRDF).
Which stock has performed better over the past year, BDTX or CRDF?
CRDF returned -54.62% over the past 12 months, compared with -54.64% for BDTX (price return, excluding dividends). Past performance does not predict future results.
Are Black Diamond Therapeutics and Cardiff Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.